Market Herald logo

Subscribe

Be the first with the news that moves the market
  • iCo Therapeutics (ICO) has completed the Phase 1b dosing for the company’s oral Amphotericin B study. 
  • Results from Phase 1b should be available before the end of 2020’s first quarter.
  • Phase 1b results will be used to improve Phase 2 of the clinical study on vulvovaginal candidiasis (VVC). 
  • iCo’s share price is down 7.14 per cent, with shares trading at $0.06 apiece.

Biotechnology company iCo Therapeutics (ICO), and its Australian subsidiary, have completed Phase 1b dosing for the oral Amphotericin B study.

The ongoing study will test how well the oral form of antifungal drug Amphotericin B can treat vulvovaginal candidiasis (VVC), a yeast infection.  

All subjects in Phase 1b of the study have received varying doses of oral Amphotericin B over 10 days. Subsequent to dosing, subjects have been followed up for an additional 10 days.

The results of the Phase 1b dosing should be available before the end of 2020’s first quarter. iCo’s Chief Medical Officer, Dr Peter Hnik, spoke about how the results will benefit the overall study.

“Results from the Phase 1b study using multiple ascending doses of oral Amphotericin B will provide additional safety and pharmacokinetic information needed for the upcoming Phase 2 clinical study in patients with vulvovaginal candidiasis.”

The Phase 2 study will compare oral Amphotericin B to Fluconazole, another antifungal medication, in a head-to-head study. The Phase 2 study is scheduled to start in 2020’s second quarter.

According to Denning et al, “Worldwide, recurrent vulvovaginal candidiasis affects about 138 million [people] annually, with a global annual prevalence of 3,871 per 100 000 [people]. 372 million [people] are affected by recurrent vulvovaginal candidiasis over their lifetime.”

“By 2030, the population of [people] with recurrent vulvovaginal candidiasis each year is estimated to increase to almost 158 million, resulting in 20,240,664 extra cases […]. In high-income countries, the economic burden from lost productivity could be up to $14.39 billion USD.

iCo’s share price is down 7.14 per cent, with shares trading at $0.06 apiece.

More From The Market Herald
Knight Therapeutics - President and CEO, Samira Sakhia.

" Knight Therapeutics (TSX:GUD) to relaunch AKYNZEO in Canada

Knight (GUD) has assumed full commercial activities for oral AKYNZEO in Canada.

" Salona Global (TSXV:SGMD) announces US$10 million private placement of debenture units

Salona Global Medical Device Corp. (SGMD) has announced its intention to embark on a private placement for gross proceeds of up to US$10,000,000.

" Therma Bright (TSXV:THRM) invests in inhalable statin technology

Therma Bright (THRM) has invested in inhalable statin treatments for respiratory conditions.

" Revive Therapeutics (CSE:RVV) announces $5M private placement

Revive Therapeutics (RVV) has announced a private placement for gross proceeds of between $3 million and $5 million.